iiinova — where your digital self keeps evolving

International Journal of Neuropsychopharmacology

@ijnp.bsky.social

81 followers 244 following 98 posts

The official journal of The International College of Neuropsychopharmacology (CINP) linktr.ee/ijnp

Posts Replies Media

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/10/2026

📢 Call for Papers: Mitochondria, Mind & Medicines Working in #mitochondrial biology, stress research, neuroscience, psychobiology, or #metabolicpsychiatry? We invite you to contribute! 🔗 Explore the topic academic.oup.com/ijnp/pages/c... #Neuropsychopharmacology #Psychiatry #Bioenergetics

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/08/2026

A recent exploratory study investigated whether the degree of antidepressant treatment resistance influences ketamine's therapeutic effects in patients with TRD. 📖 Read the article: doi.org/10.1093/ijnp...

Distinct therapeutic profiles of ketamine in treatment-resistant depression: an exploratory analysis

AbstractObjective. Intravenous ketamine demonstrates rapid efficacy for treatment-resistant depression (TRD). However, its impact on individual depressive

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/08/2026

However, when participants were stratified by ADHD severity, important differences emerged: • Moderate-to-severe unmedicated ADHD showed greater sensorimotor impairments than those receiving medication. • Mild unmedicated ADHD performed worse on visuospatial perception than medicated patients

Psychostimulant effects on motor and cognitive function in adults attention deficit hyperactivity disorder

AbstractObjectives. This study aims to compare the performance on motor and cognitive functions of adult patients with attention deficit hyperactivity diso

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/08/2026

Both ADHD groups performed worse than controls across multiple domains. Overall, psychostimulant treatment was not associated with consistent improvements in cognitive or motor performance. 📖 Read the study: doi.org/10.1093/ijnp...

Psychostimulant effects on motor and cognitive function in adults attention deficit hyperactivity disorder

AbstractObjectives. This study aims to compare the performance on motor and cognitive functions of adult patients with attention deficit hyperactivity diso

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/08/2026

Does psychostimulant treatment improve cognitive and motor performance in adults with ADHD? A recent study compared adults with medicated ADHD, unmedicated ADHD, and healthy controls across a comprehensive battery of motor and cognitive tests.

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/08/2026

The authors propose a structured framework that translates the guidelines principles into four core capabilities: • 🧩 Explainable AI • 🤝 Shared Decision-Making • 🩺 Electronic Health Record integration • 🛡️ Harm Prevention 📖 Read + doi.org/10.1093/ijnp... #ArtificialIntelligence #ClinicalGuidelines

Responsible artificial intelligence integration framework for psychiatric guidelines

Abstract. Artificial intelligence (AI) is reshaping medicine, promising advances in diagnosis, monitoring, and treatment, and psychiatry will be no excepti

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/08/2026

🔍 How can we ensure AI is safe, transparent, and accountable in psychiatry? A recent perspective in IJNP argues that responsible AI in psychiatry requires more than ethical principles. It needs practical governance frameworks that can be implemented and evaluated.

Responsible artificial intelligence integration framework for psychiatric guidelines

Abstract. Artificial intelligence (AI) is reshaping medicine, promising advances in diagnosis, monitoring, and treatment, and psychiatry will be no excepti

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/08/2026

It highlighs the potential of EEG biomarkers to support personalized treatment strategies in psychiatry. Read the study: doi.org/10.1093/ijnp... #Psychiatry #Neuropsychiatry #EEG #Biomarkers #PrecisionPsychiatry #Schizophrenia #Psychopharmacology #Cariprazine #ClinicalResearch #MentalHealth

High-density EEG study in patients with schizophrenia treated with cariprazine

Highlights Resting-state EEG captured neurophysiological changes during cariprazine treatment.Treatment response was linked to changes in resting-EEG spect

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 03/08/2026

🧠 Can EEG help predict who responds to cariprazine? A recent study by Bitter et al. found that treatment responders showed increased theta and decreased delta resting-state EEG power. Importantly, baseline gamma activity predicted treatment response with high accuracy..

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 18/06/2026

We're delighted to share that IJNP has achieved an increased Impact Factor. Strong readership and usage show that IJNP research is being discovered and used worldwide. Consider IJNP for your next paper: academic.oup.com/ijnp

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 30/05/2026

Are you attending the CINP World Congress? We invite you to visit the IJNP booth and join our dedicated sessions to meet the Editors. Connect with our editorial team, discuss your research ideas, explore future publishing opportunities! #CINP2026 #neuropsychopharmacology

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 30/05/2026

Are you attending the CINP World Congress? We invite you to visit the IJNP booth and join our dedicated sessions to meet the Editors. Connect with our editorial team, discuss your research ideas, explore future publishing opportunities! #CINP2026 #neuropsychopharmacology

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 13/05/2026

If your research fits these themes or related topics, we want to hear from you! #Neuropsychopharmacology #DrugRepurposing #Psychiatry #MedicalResearch #PsychiatryResearch #AcademicPublishing #IJNP ijnp.net/rp

IJNP Special Issue: Drug Repurposing

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 13/05/2026

We are looking for research that breathes new life into known compounds, including: 🔺Anti-inflammatory/ immunomodulatory 🔺Metabolic modulators/ insulin-signaling 🔺Cholinergic/nicotinic system 🔺Steroid hormone-related 🔺Cardiovascular + CNS 🔺Addiction-targeted 🔺Gut-brain axis ijnp.net/rp

IJNP Special Issue: Drug Repurposing

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 13/05/2026

Can existing medicines unlock new treatments for mental health? The International Journal of Neuropsychopharmacology IJNP is excited to announce a new Call for Papers for our upcoming special collection: Drug Repurposing in Psychiatry ijnp.net/rp @wegener.bsky.social @liveagodoy.bsky.social

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 26/04/2026

Same targets, different effects based on biological substrate. The conceptual and pragmatic clinical implications of dichotomizing psychotropics have several implications for driving research and clinical care. Check the paper for more: doi.org/10.1093/ijnp... #MDMA #repurposing #ketamine

Conceptual and pragmatic clinical implications of dichotomizing psychotropics as targeting physiology—physiomodal and pathology—pathomodal

Abstract. Conventional antidepressant, antipsychotics and mood stabilizing drugs share several characteristics. Firstly, they have a slow onset of action w

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 26/04/2026

based on biological substrate: → Pathomodal: conventional psychotropics—slow onset, predictive maintenance response, minimal effects in healthy individuals → Physiomodal: repurposed agents ( #psychedelics )—rapid, state-altering effects across individuals, with less certain long-term profiles

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 26/04/2026

Psychopharmacology is being reshaped by drug repurposing, and it challenges current classification systems #ibogaine We moved from indication-based to mechanism-based classification. But does that fully capture the new psychotropic landscape? A recent IJNP paper proposes a complementary distinction

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 15/03/2026

As the first study in an Asian population examining this association, the findings suggest that sweet taste preference may serve as a simple behavioral biomarker to help predict naltrexone response and support more personalized treatment strategies in AUD. Read more here: doi.org/10.1093/ijnp...

Exploring the association between sweet liking and treatment response to naltrexone in patients with alcohol use disorder

AbstractBackground. Response to naltrexone varies among individuals with alcohol use disorder (AUD). Studies in Western populations have linked the sweet-l

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 15/03/2026

Over 8 weeks, patients with the sweet-liking phenotype showed a greater reduction in alcohol consumption compared with those with a sweet-disliking. The analysis also accounted for smoking status.

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 15/03/2026

Can sweet taste preference predict response to naltrexone in alcohol use disorder (AUD)? A recent study published in IJNP evaluated whether the sweet-liking phenotype is associated with response to naltrexone treatment in Taiwanese patients with AUD.

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 20/02/2026

• Roluperidone monotherapy for negative symptoms in schizophrenia doi.org/10.1093/ijnp... • DAAO inhibition and cognitive impairment: Insights from luvadaxistat doi.org/10.1093/ijnp... • Evenamide in treatment-resistant schizophrenia: 1-year Phase 2 results doi.org/10.1093/ijnp...

Roluperidone monotherapy, a treatment for negative symptoms in schizophrenia

Abstract. Roluperidone is a drug in development targeting primary negative symptoms in schizophrenia, which binds sigma-2, 5-HT2A, and alpha1a receptors. R

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 20/02/2026

• Efficacy and Safety of KarXT (Xanomeline–Trospium) in Schizophrenia: A Systematic Review and Meta-Analysis doi.org/10.1093/ijnp... • From theory to therapy: Muscarinic receptor activation with xanomeline + trospium doi.org/10.1093/ijnp...

From theory to therapy: unlocking the potential of muscarinic receptor activation in schizophrenia with the dual M1/M4 muscarinic receptor agonist xanomeline and trospium chloride and insights from cl...

Abstract. Since the 1950s, understanding of antipsychotic activity in schizophrenia has been largely grounded in the dopamine (DA) hypothesis. Most antipsy

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 20/02/2026

Our recent collection highlights emerging therapeutic strategies targeting muscarinic, Glutamatergic, 5-HT and related pathways, bringing together clinical trial data and translational insights relevant to clinicians, researchers, and industry. Featured articles:

Efficacy and Safety of the Muscarinic Receptor Agonist KarXT (Xanomeline-Trospium) in Schizophrenia: A Systematic Review, Meta-Analysis and Bayesian Sensitivity Analysis

AbstractBackground. Schizophrenia significantly impacts global health, with existing treatments primarily focusing on positive symptoms and often causing c

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 20/02/2026

🧠Novel Targets for the Treatment of Schizophrenia: Moving Beyond Dopamine While dopamine blockade remains central to antipsychotic treatment, major unmet needs persist, particularly for negative, cognitive symptoms. Check the collection for more info: academic.oup.com/ijnp/pages/s...

Efficacy and Safety of the Muscarinic Receptor Agonist KarXT (Xanomeline-Trospium) in Schizophrenia: A Systematic Review, Meta-Analysis and Bayesian Sensitivity Analysis

AbstractBackground. Schizophrenia significantly impacts global health, with existing treatments primarily focusing on positive symptoms and often causing c

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 06/02/2026

• Early meaningful improvement often progressed to full response (mood, functioning, QoL) 📌 New Clinical avenue These data support VNS as a durable intervention that expands therapeutic options for treatment-resistant depression. Check the paper for more information: doi.org/10.1093/ijnp...

Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report

Significance Statement Patients with markedly treatment-resistant major depression have a low likelihood of benefiting from antidepressant treatments and a

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 06/02/2026

>80% of patients with clinically meaningful improvement at 12 months maintained benefit at 18 and 24 months• Low rates of loss of response over time • Delayed response observed: up to ~38% of patients without benefit at 12 months improved during the second year

Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report

Significance Statement Patients with markedly treatment-resistant major depression have a low likelihood of benefiting from antidepressant treatments and a

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 06/02/2026

🧠 Neurostimulation is redefining long-term treatment in psychiatry Vagus nerve stimulation (VNS) & sustained benefit in depression 📄 A recent paper published in IJNP reports robust long-term outcomes with VNS in MDD! 📊 Impressive findings:

Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report

Significance Statement Patients with markedly treatment-resistant major depression have a low likelihood of benefiting from antidepressant treatments and a

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 23/01/2026

🧠 Targeting glutamate uptake pathways By restoring glutamate homeostasis in a reward-relevant brain region, MC-100093 highlights a target-focused, mechanism-driven strategy for AUD pharmacotherapy. 👉 Read more on: doi.org/10.1093/ijnp... #DrugDiscovery #Pharmacology #CNSDrugs #AlcoholUseDisorder

Modulatory effects of GLT-1 enhancer, MC-100093, on glutamate uptake and associated signaling pathways in female and male alcohol preferring rats exposed to ethanol

Significance Statement This study reports the preclinical testing of novel drug, MC-100093, for the attenuation of ethanol intake. The pharmacological aspe

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 23/01/2026

🔬 Pharmacodynamic and mechanism-of-action insights MC-100093 demonstrated functional modulation of glutamatergic targets, normalizing ethanol-induced alterations within the nucleus accumbens: - GLT-1 & xCT, - NF-κB & p-Akt signalling

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 23/01/2026

💊 Preclinical pharmacology with implications for AUD drug development This study reports the preclinical evaluation of MC-100093, a novel compound that reduces voluntary ethanol intake in both male and female rats, supporting its potential as a pharmacological lead for alcohol use disorder.

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 10/01/2026

Clinical Perspective: While offering clear mechanistic and safety advantages, the optimization of DORAs continues to evolve around pharmacokinetics and next-day tolerability. Check more here: doi.org/10.1093/ijnp... #SleepMedicine #Neuropharmacology #Insomnia #Orexin #DORA #Neurology #Psychiatry

Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant

Abstract. Insomnia is a serious public health concern. As the widely prescribed hypnotics that positively modulate gamma-aminobutyric acid (GABA)A receptor

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 10/01/2026

Clinical Distinctions of DORAs: ✅ Preserved sleep architecture: Increase both NREM and REM sleep. ✅ No dependency signal: Long-term use studies show no evidence of tolerance, physical dependence, or rebound insomnia. ✅ Sustained efficacy: Demonstrated in both acute and long-term treatment.

Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant

Abstract. Insomnia is a serious public health concern. As the widely prescribed hypnotics that positively modulate gamma-aminobutyric acid (GABA)A receptor

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 10/01/2026

The Orexin System: Understanding the Modern Insomnia Treatment By pharmacologically targeting dual orexin receptor antagonists (DORAs), this class of agents promotes sleep through a fundamentally different mechanism DORAs ⬇️ the "wake drive" rather than inducing widespread neuronal inhibition

Current and novel dual orexin receptor antagonists for the treatment of insomnia: the emergence of vornorexant

Abstract. Insomnia is a serious public health concern. As the widely prescribed hypnotics that positively modulate gamma-aminobutyric acid (GABA)A receptor

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 22/12/2025

As the year draws to a close, we wish you and your loved ones a very Happy Holiday season and a peaceful, healthy, and productive New Year. We look forward to the continued collaboration of the IJNP community in 2026. On behalf of the IJNP Editorial Management Group

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 19/12/2025

Read more on: doi.org/10.1093/ijnp...

Individual differences in dopamine-related traits influence mood effects of dopamine D2-antagonist and antidepressant treatment expectations

AbstractBackground. High trait anhedonia and low trait extraversion have both been previously related to not only low state positive affect but also depres

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 19/12/2025

The bottom line: This U-shaped model moves us from trial-and-error toward precision. ✔️Prioritizing DA strategies for low-positive-affect depression. ✔️Exercising extreme caution with DA stimulation in high-trait patients. ✔️Using trait assessment to guide both pharmacological and placebo treatment

Individual differences in dopamine-related traits influence mood effects of dopamine D2-antagonist and antidepressant treatment expectations

AbstractBackground. High trait anhedonia and low trait extraversion have both been previously related to not only low state positive affect but also depres

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 19/12/2025

➡️For individuals with low positive affectivity, a dopamine precursor increased state positive affect. ➡️For individuals with high positive affectivity, the same intervention reduced state positive affect. #dopamine #precisionpsychiatry #mood #bipolar #depression #neuropsychopharmacology

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 19/12/2025

Dopamine's link to positive affect isn't linear—it could be U-shaped🧠 The recently published paper in IJNP shows that an individual's trait positive affectivity critically moderates how dopamine modulation influences state positive affect. In a double-blind design:

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 05/12/2025

🧠 Our brain circuits were shaped under these conditions, and some of the most ancient pathways remain deeply conserved across vertebrate species. This recent review highlights a fascinating framework: looking beyond mammals and exploring alternative models for studying human mental disorders.

Birds may represent a useful animal model for studying human mental disorders | Acta Neuropsychiatrica | Cambridge Core

Birds may represent a useful animal model for studying human mental disorders

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 27/11/2025

Connect with the international community of neuropsychopharmacology! Follow us across our Social Media Platforms. linktr.ee/ijnp

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 21/11/2025

Using pooled data from three Phase 3 trials, the authors show that adjunctive brexpiprazole provides meaningful symptom relief in both minimally responsive and partially responsive patients. Check the paper for more: doi.org/10.1093/ijnp...

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 21/11/2025

Editor’s Pick of the month! This month’s featured paper delivers important insights for the large group of patients with major depressive disorder who achieve only limited improvement on standard antidepressants.

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 14/11/2025

They suggest that future research should directly compare oral and depot naltrexone, systematically assess blinding, and account for comorbidities and sex differences to clarify ketamine’s mechanisms of action and guide clinical practice Check the paper for + info: doi.org/10.1093/ijnp...

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 14/11/2025

A recent commentary by @igorbandeira.bsky.social et al. highlights the steps in clinical trial design that combine ketamine and naltrexone for major depression, allowing for a mechanistic approach. @stanfordpsy.bsky.social #depression #opiod #ketamine #resistantdepression #clinicaltrials

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 14/11/2025

Opioid and Ketamine in the clinic: key methodological considerations The question of whether ketamine’s antidepressant effects are mediated by glutamatergic plasticity or opioid receptor signalling remains a subject of considerable debate.

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 07/11/2025

💊 Distinct D₂R binding poses may produce clinically meaningful differences in efficacy, onset, and tolerability 📄 Read the full study here: doi.org/10.1093/ijnp...

Partial agonist antipsychotic drugs differentially interact with a secondary binding site at the dopamine D2 receptor

Highlights - Aripiprazole and brexpiprazole showed significantly increased dissociation from the dopamine D2 receptor upon L94A mutation, indicating that t

000

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 07/11/2025

⚙️ Mechanistic insight: Aripiprazole / brexpiprazole → SBP-dependent binding → May help stabilize dopaminergic tone and reduce extrapyramidal side effects. Cariprazine / lumateperone → canonical D₂R binding, faster dynamics → Could underlie different temporal or regional dopamine modulation.

Partial agonist antipsychotic drugs differentially interact with a secondary binding site at the dopamine D2 receptor

Highlights - Aripiprazole and brexpiprazole showed significantly increased dissociation from the dopamine D2 receptor upon L94A mutation, indicating that t

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 07/11/2025

🧩 In this study, 4 clinically approved D₂R partial agonists (DPAs) were tested for how they interact w/ a secondary binding pocket (SBP) in the receptor 🔬 Key finding: Mutating a residue in the SBP(L94A) accelerated dissociation of aripiprazole and brexpiprazole, but not cariprazine or lumateperone

100

International Journal of Neuropsychopharmacology @ijnp.bsky.social · 07/11/2025

🧠 Do dopamine D₂ partial agonists all bind the same way? Maybe not. New evidence challenges the idea that all “third-generation” antipsychotics share a single D₂ receptor binding mode. #Neuropsychopharmacology #Antipsychotics #Dopamine

100